Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Construction in Progress (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Construction in Progress for 6 consecutive years, with $765000.0 as the latest value for Q4 2025.

  • Quarterly Construction in Progress rose 125.0% to $765000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $765000.0 through Dec 2025, up 125.0% year-over-year, with the annual reading at $765000.0 for FY2025, 125.0% up from the prior year.
  • Construction in Progress hit $765000.0 in Q4 2025 for Insight Molecular Diagnostics, up from $685000.0 in the prior quarter.
  • In the past five years, Construction in Progress ranged from a high of $3.1 million in Q1 2022 to a low of $263000.0 in Q2 2025.
  • Historically, Construction in Progress has averaged $1.1 million across 5 years, with a median of $696500.0 in 2023.
  • Biggest five-year swings in Construction in Progress: tumbled 85.83% in 2021 and later soared 730.52% in 2022.
  • Year by year, Construction in Progress stood at $1.2 million in 2021, then soared by 72.3% to $2.1 million in 2022, then plummeted by 66.07% to $726000.0 in 2023, then tumbled by 53.17% to $340000.0 in 2024, then soared by 125.0% to $765000.0 in 2025.
  • Business Quant data shows Construction in Progress for IMDX at $765000.0 in Q4 2025, $685000.0 in Q3 2025, and $263000.0 in Q2 2025.